Premium
Reboxetine in the maintenance therapy of depressive disorder in the elderly: a long‐term open study
Author(s) -
Aguglia Eugenio
Publication year - 2000
Publication title -
international journal of geriatric psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.28
H-Index - 129
eISSN - 1099-1166
pISSN - 0885-6230
DOI - 10.1002/1099-1166(200009)15:9<784::aid-gps189>3.0.co;2-z
Subject(s) - reboxetine , tolerability , nausea , adverse effect , medicine , depression (economics) , dysthymic disorder , somnolence , insomnia , major depressive disorder , reuptake inhibitor , psychiatry , antidepressant , macroeconomics , amygdala , hippocampus , economics
Depression in the elderly is often not recognised and is frequently under‐treated. Reboxetine is a selective noradrenaline reuptake inhibitor (selective NRI) which is effective and well tolerated in the treatment of depressed adult patients. This prospective, uncontrolled, multicentre study was designed to assess the efficacy and tolerability of reboxetine as maintenance therapy for major depressive disorder or dysthymia in 160 elderly patients (aged 65–94 years). One hundred and thirty‐nine patients completed the 6‐week run‐in period and entered the long‐term phase; 104 patients completed the 52‐week treatment period. The proportion of patients with CGI‐global improvement ratings assessed as ‘much’ and ‘very much’ improved increased from 15.1% at week 2 to 88.7% at week 6 and to 95.2% at week 52. The mean HAM‐D total score showed a reduction from 24.0 at baseline to 10.4 at week 6 and 7.5 at week 52. Twenty‐five patients discontinued treatment due to adverse events. The most frequently reported adverse events were nausea (11.9%), insomnia (11.9%), headache (10.0%) and dry mouth (9.1%), and these were of mild or moderate severity. In summary, results from this study show reboxetine to be effective, and well tolerated in both the short‐ and long‐term treatment of elderly depressed or dysthymic patients. Copyright © 2000 John Wiley & Sons, Ltd.